MetaCap

Avalyn Pharma (AVLN) vs Mineralys Therapeutics (MLYS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Avalyn Pharma is the larger company by market cap ($1.26 billion vs $1.21 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVLN-3.70%MLYS-48.74%
+37%-8%-53%
Apr 30, 20261 yearNov 20, 2026
AVLN-4.83%MLYS-53.32%
+36%-11%-58%
Apr 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVLN versus MLYS key metrics
MetricAVLNMLYS
Share price$28.40$13.66
Market cap$1.26B$1.21B
1-day change-1.05%-3.53%
YTD return—-62.36%
1-year return—-67.38%
EPS (TTM)$-3.96$-4.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-154.65M
52-week high$40.17$44.13
52-week low$22.24$13.57
Distance from 52-week high-29.30%-69.05%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+114.79%+218.89%
Average volume352.95K1.55M
Shares outstanding44.52M88.56M
Employees5676
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Avalyn Pharma

AVLN stock →

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees

About Mineralys Therapeutics

MLYS stock →

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

AVLN vs MLYS FAQ

Which is bigger, Avalyn Pharma or Mineralys Therapeutics?

Avalyn Pharma (AVLN) is larger, with a market capitalization of $1.26B compared with $1.21B for Mineralys Therapeutics (MLYS).

Are Avalyn Pharma and Mineralys Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons